The High Expression of Legumain in Canine Neoplasms: A Retrospective Analysis of 100 Cases

Ke, Chiao-Hsu; Sio, Ka-Mei; Wang, Shang-Lin; Kuo, Ying-Shiung; Huang, Wei-Hsiang; Lin, Chen-Si

doi:10.3390/ani12040504

Cited by 4 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Histopathological diagnosis was employed for all dogs with tumors. Based on the histopathological evaluation, the patients were further distributed into three groups in accordance with tumor origin [ 25 ], namely, mesenchymal-type tumors, epithelial-type tumors, and melanoma (other). Control samples (defined as “controls”) from active patients without neoplastic purpose at the National Taiwan University Veterinary Hospital were collected with owner consent.…”

Section: Methodsmentioning

confidence: 99%

Paired Analysis of D-Dimer and Its Correlated Hemostatic Parameters in 30 Dogs with Neoplasms after Tumorectomy

Liu

Wang

et al. 2023

Animals

Self Cite

View full text Add to dashboard Cite

Previous studies have reported that dogs with neoplasms had elevated D-dimer levels. However, few studies have addressed whether D-dimer could be an indicator of tumor burden. The clinical significance of paired analysis of pre- and post-operation of D-dimer levels in dogs has rarely been described. The present study investigated the values of D-dimer levels and their correlated hemostatic alterations in dogs with surgically removable benign and malignant tumors. This study analyzed 30 clinically healthy and 30 tumor-bearing dogs and evaluated the hemostatic functions including D-dimer, thromboelastography G (TEG G), fibrinogen, activated partial thromboplastin time (aPTT), prothrombin time, and platelet count. The median level of pre-treatment D-dimer was 0.8 µg/mL (range: 0.1–6.3 µg/mL), whereas the control dogs exhibited a median value of 0.1 µg/mL (range: 0.1–0.1 µg/mL, p < 0.0001). After tumorectomy, the median levels of D-dimer (p < 0.0001), fibrinogen (p < 0.0001), TEG G value (p < 0.01), and aPTT (p < 0.05) were significantly lower than those of the pre-treatment samples. However, further studies are needed to clarify the values of other hemostatic evaluations. The study revealed the clinical significance of D-dimer and its correlated hemostatic parameters by paired analysis in dogs with tumors. Though more cases are needed for solid confirmation, these values could be potential tumor biomarkers for dogs.

show abstract

Section: Methodsmentioning

confidence: 99%

Paired Analysis of D-Dimer and Its Correlated Hemostatic Parameters in 30 Dogs with Neoplasms after Tumorectomy

Liu

Wang

et al. 2023

Animals

Self Cite

View full text Add to dashboard Cite

show abstract

“…The slides were separately analyzed by two veterinary pathologists who were blinded to the experimental story. Sections in necrotic areas or located in the margins of the tissues were excluded from consideration to avoid artifacts [28].…”

Section: Immunofluorescence Staining and Analysismentioning

confidence: 99%

Tumors Established in a Defective Immune Environment Reprogram the Oncogenic Signaling Pathways to Escalate Tumor Antigenicity

Ke,

Wu,

Wang

et al. 2024

Biomedicines

Self Cite

View full text Add to dashboard Cite

Tumors developed in immunocompromised hosts are more immunogenic. However, few studies have addressed the potential mechanisms underlying the high immunogenicity of tumors found in a suppressed immune system. Therefore, we aimed to elucidate the impacts of the immune system on tumor behaviors and immunogenicity sculpting. A murine colorectal adenocarcinoma cell line, CT26wt, was administrated into immunocompetent (BALB/c) and immunocompromised (NOD.SCID) mice, respectively. On day 11, the CT26 cells slowly progressed in the NOD.SCID mice compared to the BALB/c mice. We then performed liquid chromatography–tandem mass spectrometry (LC-MS/MS) and analyzed the differentially expressed proteins (DEPs). The DEPs participated in numerous oncogenic pathways, PI3K/AKT/mTOR cell signaling, and the silencing of several tumor suppressors, such as PTEN and RBL1, during tumorigenesis. On day 34, the CT26/SCID tumors inversely became malignant counterparts; then the CT26/SCID tumors were harvested and re-inoculated into immunocompetent mice (CT26/SCID-Re tumors) to determine the immunogenicity. The CT26/SCID-Re tumor growth rate significantly decreased. Furthermore, increased infiltrations of dendritic cells and tumor-infiltrating T lymphocytes were found in the CT26/SCID-Re tumors. These findings suggest that immunogenic tumors might express multiple tumor rejection antigens, unlike wild-type tumors, and attract more immune cells, therefore decreasing the growth rate. Collectively, our study first revealed that in immunodeficient hosts, tumor suppressors were silenced and oncogenic signaling pathways were changed during the initial phase of tumor development. With tumor progression, the tumor antigens were overexpressed, exhibiting elevated immunogenicity. This study offers a hint on the mechanisms of tumorigenesis and provides a niche for investigating the interaction between host immunity and cancer development.

show abstract

“…In summary, nanoformulations have found a wide range of applications in neoplasms; however, it is currently impossible to distinguish the development of veterinary and human approaches to cancer treatment using nanotechnology [ 117 ]. The period of knowledge accumulation in this direction involves the widespread use of animal models to understand general mechanisms [ 118 ].…”

Section: Current Applications Of Nanomaterials In Veterinary Medicinementioning

confidence: 99%

Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine

Danchuk,

Levchenko,

da Silva Mesquita

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

In recent decades, nanotechnology has been rapidly advancing in various fields of human activity, including veterinary medicine. The review presents up-to-date information on recent advancements in nanotechnology in the field and an overview of the types of nanoparticles used in veterinary medicine and animal husbandry, their characteristics, and their areas of application. Currently, a wide range of nanomaterials has been implemented into veterinary practice, including pharmaceuticals, diagnostic devices, feed additives, and vaccines. The application of nanoformulations gave rise to innovative strategies in the treatment of animal diseases. For example, antibiotics delivered on nanoplatforms demonstrated higher efficacy and lower toxicity and dosage requirements when compared to conventional pharmaceuticals, providing a possibility to solve antibiotic resistance issues. Nanoparticle-based drugs showed promising results in the treatment of animal parasitoses and neoplastic diseases. However, the latter area is currently more developed in human medicine. Owing to the size compatibility, nanomaterials have been applied as gene delivery vectors in veterinary gene therapy. Veterinary medicine is at the forefront of the development of innovative nanovaccines inducing both humoral and cellular immune responses. The paper provides a brief overview of current topics in nanomaterial safety, potential risks associated with the use of nanomaterials, and relevant regulatory aspects.

show abstract

The High Expression of Legumain in Canine Neoplasms: A Retrospective Analysis of 100 Cases

Cited by 4 publications

References 31 publications

Paired Analysis of D-Dimer and Its Correlated Hemostatic Parameters in 30 Dogs with Neoplasms after Tumorectomy

Paired Analysis of D-Dimer and Its Correlated Hemostatic Parameters in 30 Dogs with Neoplasms after Tumorectomy

Tumors Established in a Defective Immune Environment Reprogram the Oncogenic Signaling Pathways to Escalate Tumor Antigenicity

Meeting Contemporary Challenges: Development of Nanomaterials for Veterinary Medicine

Contact Info

Product

Resources

About